Herpes Vaccine in Development Achieves Phase 2 Study Goals; CBCD Reviews a Report

An in-development vaccine significantly reduced HSV viral activity in clinical trials. (1)

ROCHESTER, NEW YORK, UNITED STATES, May 22, 2015 /EINPresswire.com/ --

“Infected with the herpes simplex virus (HSV-1 or HSV-2)? The CBCD recommends taking Gene-Eden-VIR or Novirin.” – Greg Bennett, CBCD

There are no herpes vaccines on the market today. However, a herpes vaccine in development reduced the activity of the herpes virus in a mid-stage clinical trial. The vaccine candidate “works by galvanizing the body’s T and B cells to attack herpes, and, in a 310-patient trial, the vaccine significantly beat out placebo in tamping down viral activity.” (1) Specifically, the vaccine candidate significantly reduced viral shedding. Scientists are excited by these results, and stock prices for Genocea Biosciences' ($GNCA) skyrocketed following the announcement of the vaccine candidate’s success. (1)

Scientists around the globe are working furiously to develop an effective HSV vaccine, and are pursuing different methods to do so. Dr. William Jacobs, Jr., a lead researcher for another vaccine candidate, said that “Developing a herpes vaccine is one of the holy grails of infectious disease research. We decided to take an approach that runs counter to most of the tactics used by other scientists - and we seem to have cracked the code.” (2) Additionally, Dr. Jacobs, Jr. said that “With herpes sores you continually get them. If our vaccine works in humans as it does in mice, administering it early in life could completely eliminate herpes latency.” (3) Effectively, this would also eliminate recurrent herpes outbreaks.

researching the effect of foreign DNA, such as that found in latent viruses, on human cells. Since 2003, the CBCD has warned of the dangers latent viruses pose. The Center believes removing herpes from the long list of chronic diseases will be an important step forward for medicine.

However, developing an effective, therapeutic vaccine against the genital herpes virus (HSV-2) and gaining FDA approval takes time. Until the Genocea and Yeshiva University's anti-herpes vaccines are FDA approved, the CBCD recommends that infected individuals take Gene-Eden-VIR or Novirin, natural herpes remedies with a formula backed by clinical studies.

Click to learn more about herpes symptoms.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the formula is effective against the herpes family of viruses, including HSV-1 and HSV-2. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the HSV … reported a safe decrease in their symptoms following treatment with (the formula of Novirin)." (4) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (4)

Gene-Eden-VIR and Novirin can be ordered online on their product websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims. Note: Novirin has the same formula as Gene-Eden-VIR. However, it contains higher quality and more expensive ingredients.

"Herpes simplex virus (HSV) infections impose an enormous health burden on the world's population, making the development of an HSV vaccine a top public health priority. HSV-1 is the leading cause of corneal blindness worldwide and has emerged as the predominant cause of genital disease in the developed world. HSV-2 is the leading cause of genital ulcerative disease, and its high prevalence in sub-Saharan Africa contributes significantly to the spread of HIV-1 in this region. Moreover, HSV can lie dormant (or latent) in neurons for months or years before becoming active, so the health of infected individuals can be affected for life. There is, therefore, an urgent need for an effective HSV vaccine that can provide protection against infection and also prevent the virus entering a latent state." (5)

What treatments are currently available for those infected with the herpes virus?

“Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day.” (4)

The CBCD points out that there is also the natural antiviral products, Gene-Eden-VIR and Novirin, with a formula designed to help the immune system target the latent HSV in those already infected. Additionally, two separate post-marketing clinical studies found that their formula reduced the symptoms of HSV infected individuals. (4)

“We believe a vaccine that is effective against both the active and latent herpes virus will be a medical breakthrough. But, in light of the fact that there are no vaccines against the herpes virus currently on the market, the CBCD recommends that HSV infected individuals take Gene-Eden-VIR or Novirin against the latent HSV.” – Greg Bennett, CBCD

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Garde, D. "Genocea's herpes vaccine hits the mark in Phase II" Published May 20, 2015
http://www.fiercebiotech.com/story/genoceas-herpes-vaccines-hits-mark-phase-ii/2015-05-20

(2) Albert Einstein College of Medicine - Yeshiva University - "Experimental Herpes Vaccine Upends Traditional Approach and Shows Promise." Published March 10, 2015
http://www.einstein.yu.edu/news/releases/1076/experimental-herpes-vaccine-upends-traditional-approach-and-shows-promise/

(3) Howard Hughes Medical Institute (HHMI) - Radical Vaccine Design Effective Against Herpes Viruses. Published March 7, 2015.
http://www.hhmi.org/news/radical-vaccine-design-effective-against-herpes-viruses

(4) Polansky, H., Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VH2qQNKUf90

(5) Elifesciences.org - Bolland, S., Pierce,S. "Ups and downs in the search for a Herpes simplex virus vaccine." Published March 10, 2015.
http://elifesciences.org/content/elife/4/e06883.full.pdf

Hanan Polansky
Lilac Corp.
5852509999
email us here
